September 2, 2016 4:58pm

… I intend to melt some ice in a distilled beverage and devour those marinated olives as I contemplate September and recover

 

Pre-open indication’s tally:  3 hits (BSTG, MDXG and VTGN) and 2 miss (AGTC and ONCE)

Do you care what happened today, you should … because it has implications to Monday's sector activity?  

 

I answer one question; in which company should investors put, keep and commit their money!

 

The freebies are ending; if you are a subscriber, you are safe in reading post Labor Day!  You don’t want to get left behind the updates to a trade!

 

 

There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.

 

 

The three major indexes posting weekly gains, following a disappointing employment report.

The NASDAQ closed UP +22.69 or +0.43% to 5,249.90 and the DOW closed UP +72.66 or +0.39% to 18,491.96.

 

 

A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:   

  • The open was negative with an A/DL of 12/29 and 2 flats;
  • The mid-day stayed negative with an A/DL of 20/21 and 2 flats;
  • The closing bell flipped neutral with A/DL of 19/19 and 5 flats;

 

 

Henry’omics:

The stem, cell, gene and regenerative therapy (SCGT&RT) sector was negative at the opening bell, stayed negative at the mid-day with the sector closing neutral.

  • I would start checking the gas tank in sector companies for September to see who can go the distance …

 

Thank you all who emailed and called; the post recuperative is going well – I can now have a cocktail … which means I am well on the road to recovery!

 

Call me cantankerous, contrarian or even a curmudgeon but at the least I get it right and investors make money!

 

 

Pre-open indication’s tally:  3 hit and 2 miss:

  • Applied Genetic Technologies (AGTC) closed DOWN -$0.13 – miss;
  •  Biostage (BSTG) closed SOWN -$0.03 – hit;
  • MiMedx Group (MDXG) closed UP +$0.20 – hit;
  • Spark Therapeutics (ONCE) closed UP +$0.59 – miss;
  • VistaGen (VTGN) closed DOWN - $0.06 – hit;

 

 

Today’s Bottom Line:

“Our” universe is soft on expectations!

 

 

Review my fear gauge or the CBOE Volatility Index (VIX):

  • Friday traded near 12.2;
  • Thursday traded near 13.5;
  • Wednesday traded near 13.5;
  • Tuesday traded 13.4;
  • Monday traded 13.1;
  • Last Friday traded near 13.65;

 

 

Decliners:

  • ImmunoCellular (NYSEMKT: IMUC) -5.77%;
  • Neuralstem (CUR) 4.82%;
  • Juno Therapeutics (JUNO) -2.90%;
  • Fate Therapeutics (FATE) -2.86%;
  • Biostage (BSTG) -2.70%

 

Advancers:

  • International Stem Cell (ISCO) +10%;
  • BioLife Solutions (BLFS) +6.17%;
  • Adverum (ADVM) +5.35%;
  • Asterias Biotherapeutics (NYSEMKT: AST) +4.96%;
  • Capricor (CAPR) +4.40%

 

Flat:

  • Cellectis SA (CLLS) at $26.40;
  • Cytori (CYTX) at $2.05;
  • StemCells (STEM) at $1.54;
  • uniQure (QURE) at $7.70;
  • ReNeuron (RENE.L) at $2.75                                                               

                                                                                                  

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.